<?xml version='1.0' encoding='utf-8'?>
<document id="15968883"><sentence text="Lack of pharmacokinetic drug-drug interaction between ciclesonide and erythromycin."><entity charOffset="54-65" id="DDI-PubMed.15968883.s1.e0" text="ciclesonide" /><entity charOffset="70-82" id="DDI-PubMed.15968883.s1.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.15968883.s1.e0" e2="DDI-PubMed.15968883.s1.e0" /><pair ddi="false" e1="DDI-PubMed.15968883.s1.e0" e2="DDI-PubMed.15968883.s1.e1" /></sentence><sentence text="To investigate whether systemic exposure to desisobutyrylciclesonide (des-CIC) (the pharmacologically active metabolite of ciclesonide) and erythromycin are affected by combined administration of ciclesonide and erythromycin"><entity charOffset="44-68" id="DDI-PubMed.15968883.s2.e0" text="desisobutyrylciclesonide" /><entity charOffset="70-77" id="DDI-PubMed.15968883.s2.e1" text="des-CIC" /><entity charOffset="123-134" id="DDI-PubMed.15968883.s2.e2" text="ciclesonide" /><entity charOffset="140-152" id="DDI-PubMed.15968883.s2.e3" text="erythromycin" /><entity charOffset="196-207" id="DDI-PubMed.15968883.s2.e4" text="ciclesonide" /><entity charOffset="212-224" id="DDI-PubMed.15968883.s2.e5" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e0" e2="DDI-PubMed.15968883.s2.e0" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e0" e2="DDI-PubMed.15968883.s2.e1" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e0" e2="DDI-PubMed.15968883.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e0" e2="DDI-PubMed.15968883.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e0" e2="DDI-PubMed.15968883.s2.e4" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e0" e2="DDI-PubMed.15968883.s2.e5" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e1" e2="DDI-PubMed.15968883.s2.e1" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e1" e2="DDI-PubMed.15968883.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e1" e2="DDI-PubMed.15968883.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e1" e2="DDI-PubMed.15968883.s2.e4" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e1" e2="DDI-PubMed.15968883.s2.e5" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e2" e2="DDI-PubMed.15968883.s2.e2" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e2" e2="DDI-PubMed.15968883.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e2" e2="DDI-PubMed.15968883.s2.e4" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e2" e2="DDI-PubMed.15968883.s2.e5" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e3" e2="DDI-PubMed.15968883.s2.e3" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e3" e2="DDI-PubMed.15968883.s2.e4" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e3" e2="DDI-PubMed.15968883.s2.e5" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e4" e2="DDI-PubMed.15968883.s2.e4" /><pair ddi="false" e1="DDI-PubMed.15968883.s2.e4" e2="DDI-PubMed.15968883.s2.e5" /></sentence><sentence text="" /><sentence text="18 healthy subjects were enrolled in a Phase 1, open-label, randomized, three-period crossover study" /><sentence text=" Each subject received ciclesonide (640 microg ex-actuator, equivalent to 800 microg ex-valve, via hydrofluoroalkane metered-dose inhaler) and erythromycin (500 mg PO), separately and in combination, in random order"><entity charOffset="23-34" id="DDI-PubMed.15968883.s5.e0" text="ciclesonide" /><entity charOffset="99-116" id="DDI-PubMed.15968883.s5.e1" text="hydrofluoroalkane" /><entity charOffset="143-155" id="DDI-PubMed.15968883.s5.e2" text="erythromycin" /><entity charOffset="164-166" id="DDI-PubMed.15968883.s5.e3" text="PO" /><pair ddi="false" e1="DDI-PubMed.15968883.s5.e0" e2="DDI-PubMed.15968883.s5.e0" /><pair ddi="false" e1="DDI-PubMed.15968883.s5.e0" e2="DDI-PubMed.15968883.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15968883.s5.e0" e2="DDI-PubMed.15968883.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15968883.s5.e0" e2="DDI-PubMed.15968883.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15968883.s5.e1" e2="DDI-PubMed.15968883.s5.e1" /><pair ddi="false" e1="DDI-PubMed.15968883.s5.e1" e2="DDI-PubMed.15968883.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15968883.s5.e1" e2="DDI-PubMed.15968883.s5.e3" /><pair ddi="false" e1="DDI-PubMed.15968883.s5.e2" e2="DDI-PubMed.15968883.s5.e2" /><pair ddi="false" e1="DDI-PubMed.15968883.s5.e2" e2="DDI-PubMed.15968883.s5.e3" /></sentence><sentence text=" Blood samples were collected at timed intervals to determine serum concentrations of erythromycin, des-CIC, and ciclesonide using HPLC-MS detection"><entity charOffset="86-98" id="DDI-PubMed.15968883.s6.e0" text="erythromycin" /><entity charOffset="100-107" id="DDI-PubMed.15968883.s6.e1" text="des-CIC" /><entity charOffset="113-124" id="DDI-PubMed.15968883.s6.e2" text="ciclesonide" /><pair ddi="false" e1="DDI-PubMed.15968883.s6.e0" e2="DDI-PubMed.15968883.s6.e0" /><pair ddi="false" e1="DDI-PubMed.15968883.s6.e0" e2="DDI-PubMed.15968883.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15968883.s6.e0" e2="DDI-PubMed.15968883.s6.e2" /><pair ddi="false" e1="DDI-PubMed.15968883.s6.e1" e2="DDI-PubMed.15968883.s6.e1" /><pair ddi="false" e1="DDI-PubMed.15968883.s6.e1" e2="DDI-PubMed.15968883.s6.e2" /></sentence><sentence text=" Adverse events were recorded throughout the study" /><sentence text="" /><sentence text="Combined administration of ciclesonide and erythromycin did not alter the pharmacokinetics (PK) of either drug"><entity charOffset="27-38" id="DDI-PubMed.15968883.s9.e0" text="ciclesonide" /><entity charOffset="43-55" id="DDI-PubMed.15968883.s9.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.15968883.s9.e0" e2="DDI-PubMed.15968883.s9.e0" /><pair ddi="false" e1="DDI-PubMed.15968883.s9.e0" e2="DDI-PubMed.15968883.s9.e1" /></sentence><sentence text=" The serum concentration vs" /><sentence text=" time profiles of erythromycin, des-CIC, and ciclesonide were similar when ciclesonide and erythromycin were administered separately or together"><entity charOffset="18-30" id="DDI-PubMed.15968883.s11.e0" text="erythromycin" /><entity charOffset="32-39" id="DDI-PubMed.15968883.s11.e1" text="des-CIC" /><entity charOffset="45-56" id="DDI-PubMed.15968883.s11.e2" text="ciclesonide" /><entity charOffset="75-86" id="DDI-PubMed.15968883.s11.e3" text="ciclesonide" /><entity charOffset="91-103" id="DDI-PubMed.15968883.s11.e4" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e0" e2="DDI-PubMed.15968883.s11.e0" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e0" e2="DDI-PubMed.15968883.s11.e1" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e0" e2="DDI-PubMed.15968883.s11.e2" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e0" e2="DDI-PubMed.15968883.s11.e3" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e0" e2="DDI-PubMed.15968883.s11.e4" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e1" e2="DDI-PubMed.15968883.s11.e1" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e1" e2="DDI-PubMed.15968883.s11.e2" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e1" e2="DDI-PubMed.15968883.s11.e3" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e1" e2="DDI-PubMed.15968883.s11.e4" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e2" e2="DDI-PubMed.15968883.s11.e2" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e2" e2="DDI-PubMed.15968883.s11.e3" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e2" e2="DDI-PubMed.15968883.s11.e4" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e3" e2="DDI-PubMed.15968883.s11.e3" /><pair ddi="false" e1="DDI-PubMed.15968883.s11.e3" e2="DDI-PubMed.15968883.s11.e4" /></sentence><sentence text=" In addition, the PK characteristics of erythromycin and des-CIC were equivalent following single or co-administration"><entity charOffset="40-52" id="DDI-PubMed.15968883.s12.e0" text="erythromycin" /></sentence><sentence text=" Point estimates (90% confidence intervals (CI)) for erythromycin were as follows: AUC0-inf, 0"><entity charOffset="53-65" id="DDI-PubMed.15968883.s13.e0" text="erythromycin" /></sentence><sentence text="96 (0" /><sentence text="79, 1" /><sentence text="18); Cmax, 1" /><sentence text="00 (0" /><sentence text="84, 1" /><sentence text="20); and t1/2, 0" /><sentence text="96 (0" /><sentence text="83, 1" /><sentence text="12)" /><sentence text=" The following point estimates (90% CI) were obtained for des-CIC: AUC0-inf, 1" /><sentence text="16 (1" /><sentence text="03, 1" /><sentence text="30); Cmax, 1" /><sentence text="06 (0" /><sentence text="98, 1" /><sentence text="15); and t1/2, 1" /><sentence text="04 (0" /><sentence text="96, 1" /><sentence text="13)" /><sentence text=" Lack of ciclesonide/erythromycin interaction was demonstrated as the 90% CI of AUC0-inf, Cmax, and t1/2 of both compounds were entirely within the stipulated equivalence range of 0"><entity charOffset="9-20" id="DDI-PubMed.15968883.s33.e0" text="ciclesonide" /><entity charOffset="21-33" id="DDI-PubMed.15968883.s33.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.15968883.s33.e0" e2="DDI-PubMed.15968883.s33.e0" /><pair ddi="false" e1="DDI-PubMed.15968883.s33.e0" e2="DDI-PubMed.15968883.s33.e1" /></sentence><sentence text="67 - 1" /><sentence text="50" /><sentence text=" No study drug-related adverse events occurred during this study" /><sentence text="" /><sentence text="Combined administration of ciclesonide and erythromycin did not alter the PK properties of either drug"><entity charOffset="27-38" id="DDI-PubMed.15968883.s38.e0" text="ciclesonide" /><entity charOffset="43-55" id="DDI-PubMed.15968883.s38.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.15968883.s38.e0" e2="DDI-PubMed.15968883.s38.e0" /><pair ddi="false" e1="DDI-PubMed.15968883.s38.e0" e2="DDI-PubMed.15968883.s38.e1" /></sentence><sentence text=" Both drugs were safe and well-tolerated" /><sentence text=" Therefore, systemic exposure to ciclesonide or erythromycin is not increased in patients receiving concomitant therapy"><entity charOffset="33-44" id="DDI-PubMed.15968883.s40.e0" text="ciclesonide" /><entity charOffset="48-60" id="DDI-PubMed.15968883.s40.e1" text="erythromycin" /><pair ddi="false" e1="DDI-PubMed.15968883.s40.e0" e2="DDI-PubMed.15968883.s40.e0" /><pair ddi="false" e1="DDI-PubMed.15968883.s40.e0" e2="DDI-PubMed.15968883.s40.e1" /></sentence><sentence text="" /></document>